KR880009016A - 마이코페놀산의 모르폴리노에틸에스테르 및 이의 유도체 - Google Patents

마이코페놀산의 모르폴리노에틸에스테르 및 이의 유도체 Download PDF

Info

Publication number
KR880009016A
KR880009016A KR870014353A KR870014353A KR880009016A KR 880009016 A KR880009016 A KR 880009016A KR 870014353 A KR870014353 A KR 870014353A KR 870014353 A KR870014353 A KR 870014353A KR 880009016 A KR880009016 A KR 880009016A
Authority
KR
South Korea
Prior art keywords
compound
formula
hydrogen
pharmaceutically acceptable
lower alkyl
Prior art date
Application number
KR870014353A
Other languages
English (en)
Other versions
KR940003758B1 (ko
Inventor
에이취.넬슨 페터
구 치-리앙 리
시. 앨 리슨 안토니
엠.유구이 엘지에
에이.리 윌리암
Original Assignee
헤르비그 본 모제
신텍스(유.에스.에이.)인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21733252&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR880009016(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 헤르비그 본 모제, 신텍스(유.에스.에이.)인코포레이티드 filed Critical 헤르비그 본 모제
Publication of KR880009016A publication Critical patent/KR880009016A/ko
Application granted granted Critical
Publication of KR940003758B1 publication Critical patent/KR940003758B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음.

Description

마이코페놀산의 모르폴리노에틸에스테르 및 이의 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 하기 일반식 (A)의 화합물 및 이의 약제학적 허용염.
    상기식에서, Z는 수소 또는 -C(O)R (여기서 R은 저급 알킬 또는 아릴이다)이다.
  2. 제1항에 있어서, Z가 수소인 화합물.
  3. 제1항에 있어서, Z가 수소인 화합물의 염산염.
  4. 제1항에 있어서, Z가 수소인 화합물의 황산염 또는 중황산염.
  5. 제1항에 있어서, Z가 수소인 화합물의 중황산염.
  6. 제1항에 있어서, R이 저급 알킬인 화합물.
  7. 제6항에 있어서, Z가 -C(O)CH3인 화합물.
  8. 제6항에 있어서, Z가 -C(O)CH3인 화합물의 염산염.
  9. 제6항에 있어서, Z가 -C(O)CH2CH3인 화합물.
  10. 제6항에 있어서, Z가 -C(O)(CH3)3인 화합물.
  11. 제1항에 있어서, Z가 -C(O)C6H5인 화합물.
  12. 약제학적 허용 비독성 부형제 및 하기 일반식 (A)의 화합물 또는 이의 약제학적 허용염의 치료학적 유효량을 함유하는 약제학적 조성물.
    상기식에서, Z는 수소 또는 -C(O)R (여기서 R은 저급 알킬 또는 아릴이다)이다.
  13. 하기 일반식 (A)의 화합물 또는 이의 약제학적 허용염의 치료학적 유효량을 포유동물에 투여함으로써, 포유동물의 자기면역증, 염증, 건선증, 종양, 바이러스, 및 류마티스성 관절염을 치료하는 방법.
    상기식에서, Z는 수소 또는 -C(O)R (여기서 R은 저급 알킬 또는 아릴이다).
  14. (a) 일반식 (a)의 화합물을 모르폴리노에탄올과 반응시켜 일반식 (A)의 화합물을 형성시키거나 ; (b) 일반식 (b)의 화합물을 모르폴리노에탄올 및 카보디이미드와 반응시켜 일반식 (A)의 화합물을 형성시키거나 ; (c) Z가 수소인 일반식 (A)의 화합물을 염기의 존재하에 아실 할라이드 또는 무수 아실과 반응시켜 Z가 -C(O)R인 일반식 (A)의 화합물을 형성시키거나 ; (d) Z가 -C(O)R인 일반식 (A)의 화합물을 염기 또는 아민과 반응시켜 Z가 수소인 일반식 (A)의 화합물을 형성시키거나 ; (e) 일반식 (A)의 화합물을 일반식 (A) 화합물의 약제학적 허용 산부가염으로 전환시키거나 ; (f) 일반식 (A) 화합물의 약제학적 허용 산부가염을 일반식 (A)의 상응하는 유리 화합물로 전환시키거나 ; (g) 일반식 (A) 화합물의 하나의 약제학적 허용 산부가염을 일반식 (A) 화합물의 다른 약제학적 허용 산부가염을 전환시키거나 ; (h) Z가 -C(O)R인 일반식 (A)의 화합물을 에스테르 대 에스테르 교환에 의해 Z가 -C(O)R인 다른 일반식 (A)의 화합물로 전환시킴을 포함하는 일반식 (A)의 화합물 또는 이의 약제학적 허용염을 제조하는 방법.
    상기식에서, Z는 수소 또는 -C(O)R (여기서 R은 저급 알킬 또는 아릴이다)이고 : X는 할로겐이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870014353A 1987-01-30 1987-12-15 마이코페놀산의 모르폴리노에틸 에스테르 및 이의 유도체 KR940003758B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/008,717 1987-01-30
US07/008,717 US4753935A (en) 1987-01-30 1987-01-30 Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US008717 1987-01-31

Publications (2)

Publication Number Publication Date
KR880009016A true KR880009016A (ko) 1988-09-13
KR940003758B1 KR940003758B1 (ko) 1994-04-30

Family

ID=21733252

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870014353A KR940003758B1 (ko) 1987-01-30 1987-12-15 마이코페놀산의 모르폴리노에틸 에스테르 및 이의 유도체

Country Status (26)

Country Link
US (7) US4753935A (ko)
EP (1) EP0281713B1 (ko)
JP (1) JPS63188672A (ko)
KR (1) KR940003758B1 (ko)
AT (1) ATE68180T1 (ko)
AU (1) AU599728B2 (ko)
CA (1) CA1333285C (ko)
DE (2) DE19675020I2 (ko)
DK (1) DK166675B1 (ko)
ES (1) ES2038190T3 (ko)
FI (1) FI85141C (ko)
GE (1) GEP20094816B (ko)
GR (1) GR3002866T3 (ko)
HK (1) HK125893A (ko)
HU (2) HU201927B (ko)
IE (1) IE60750B1 (ko)
IL (1) IL84833A (ko)
LU (1) LU88795I2 (ko)
LV (1) LV5748B4 (ko)
MX (1) MX9203163A (ko)
NL (1) NL960019I2 (ko)
NO (2) NO171680C (ko)
NZ (1) NZ222922A (ko)
PH (1) PH23819A (ko)
PT (1) PT86343B (ko)
ZA (1) ZA879414B (ko)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177072A (en) * 1987-01-30 1993-01-05 Syntex (U.S.A.) Inc. Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives
WO1990009788A1 (en) * 1989-02-23 1990-09-07 The University Of North Carolina At Chapel Hill Etoposide analogues
US5219851A (en) * 1991-03-05 1993-06-15 Warner-Lambert Company Tetrahydroisoquinoline-type renin inhibiting peptides
US5247083A (en) * 1992-07-10 1993-09-21 Syntex (U.S.A.) Inc. Direct esterification of mycophenolic acid
WO1994012184A1 (en) * 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
DE69421280T2 (de) * 1993-06-25 2000-07-13 Main Camp Marketing Pty Ltd Therapeutisches agens
ATE173475T1 (de) * 1993-09-15 1998-12-15 Syntex Inc Kristallines, wasserfreies mofetilmycophenolat und zubereitungen zu deren intravenösen anwendung
CN1089583C (zh) * 1993-10-01 2002-08-28 辛泰克斯（美国）公司 霉酚酸2－(4－吗啉代)乙酯高剂量口服悬浮剂
US5512568A (en) * 1994-02-18 1996-04-30 Syntex (U.S.A.) Inc. Method of using 4-amino derivatives of 5-substituted mycophenolic acid
US5444072A (en) * 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US5525602A (en) * 1994-02-18 1996-06-11 Syntex (U.S.A.) Inc. Method of using 4-amino 6-substituted mycophenolic acid and derivatives
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US5493030A (en) * 1994-02-18 1996-02-20 Syntex (U.S.A.) Inc. 5-substituted derivatives of mycophenolic acid
US6225073B1 (en) 1994-07-07 2001-05-01 Dade Behring Marburg Gmbh Immunoassay for mycophenolic acid
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US6596747B2 (en) 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
US6420403B1 (en) 1998-10-29 2002-07-16 Edwin J. Iwanowicz Inhibitors of IMPDH enzyme
CA2348267A1 (en) * 1998-10-29 2000-05-11 Henry H. Gu Novel inhibitors of impdh enzyme
AU764479B2 (en) 1998-10-29 2003-08-21 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
IN188985B (ko) 1998-12-09 2002-11-30 Biocon Ltd
US6514979B1 (en) 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
US6107052A (en) * 1999-06-09 2000-08-22 Roche Diagnostics Corporation Enzymatic measurement of mycophenolic acid
EP1276739A2 (en) * 2000-04-24 2003-01-22 Bristol-Myers Squibb Company Heterocycles that are inhibitors of impdh enzyme
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
WO2004012746A2 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California New uses for inhibitors of inosine monophosphate dehydrogenase
TWI221414B (en) * 2003-02-21 2004-10-01 Chunghwa Chemical Synthesis & Method of making mycophenolate mofetil using transesterification
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
AU2003231924A1 (en) * 2003-04-07 2004-11-01 Biocon Limited Microwave synthesis of mycophenolate
ES2327639T3 (es) * 2003-05-14 2009-11-02 Dsm Ip Assets B.V. Uso de derivados de ftalida para el tratamiento y prevecion de diabetes mellitus.
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
EP1667987B1 (en) * 2003-09-11 2008-07-23 Sandoz AG Process for the production of mycophenolate mofetil
WO2005027661A1 (en) * 2003-09-23 2005-03-31 Dsm Ip Assets B.V. Compositions for the treatment and prevention of diabetes mellitus
WO2005033089A1 (en) * 2003-10-07 2005-04-14 Biocon Limited Salt of 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid with n, n-dimethyl-imidodicarbonimidic diamide
US7683188B2 (en) * 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
JP2007534697A (ja) * 2004-04-27 2007-11-29 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸モフェチルおよび他のミコフェノール酸エステルの調製方法
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US7439373B2 (en) * 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
JP2008517584A (ja) * 2004-08-16 2008-05-29 アディポジェン ファーマシューティカルズ ピーティーワイ リミテッド 代謝調節薬剤およびそのための使用
CA2533326C (en) * 2005-01-20 2012-01-03 Apotex Fermentation Inc. An improved process for the preparation of mycophenolate mofetil
EP1917010A2 (en) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Compositions and methods for treating vascular, autoimmune and inflammatory diseases
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
CN100402516C (zh) * 2005-10-18 2008-07-16 深圳市东阳光实业发展有限公司 一种霉酚酸莫啡酯的制备方法
CN101378749A (zh) * 2006-02-13 2009-03-04 诺瓦提斯公司 高剂量的麦考酚酸(mpa)
WO2008003637A2 (en) * 2006-07-05 2008-01-10 Dsm Ip Assets B.V. Isolation and use of amine salts of mycophenolic acid
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
US20080188653A1 (en) 2007-02-04 2008-08-07 Formosa Laboratories, Inc. Process for Preparation of Mycophenolate Mofetil
CN100484930C (zh) * 2007-03-16 2009-05-06 重庆大新药业股份有限公司 一种吗替麦考酚酯的制备方法
WO2009000834A1 (en) * 2007-06-27 2008-12-31 Dsm Ip Assets B.V. Method for the purification of mycophenolate mofetil
WO2009010503A1 (en) * 2007-07-18 2009-01-22 Dsm Ip Assets B.V. Mycophenolic acid recycling in a method for the preparation of mycophenolate mofetil
US20090076000A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched mycophenolate mofetil
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
WO2009084008A1 (en) * 2007-12-28 2009-07-09 Cadila Healthcare Limited Process for preparing mycophenolate mofetil
KR100975520B1 (ko) * 2008-02-01 2010-08-12 종근당바이오 주식회사 마이코페놀레이트 모페틸의 개선된 제조방법
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2310008A4 (en) * 2008-07-09 2014-03-05 Aspreva Internat Ltd MYCOPHENOLIC SODIUM ACID SOLUTIONS WITH PH SPECIFIC FOR THE TREATMENT OF OCULAR DISORDERS
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8716262B2 (en) * 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8551973B2 (en) * 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
FI124873B (fi) 2009-10-06 2015-02-27 Maricap Oy Menetelmä ja laitteisto pneumaattisessa materiaalinsiirtojärjestelmässä
FI20096026L (fi) 2009-10-06 2011-04-07 Maricap Oy Menetelmä ja laitteisto pneumaattisessa materiaalinsiirtojärjestelmässä
CN104017020B (zh) 2010-03-31 2017-04-12 吉利德制药有限责任公司 核苷氨基磷酸酯
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
CN102952105A (zh) * 2011-08-26 2013-03-06 中国科学院上海药物研究所 一类霉酚酸衍生物、其制备方法和用途
WO2013041205A1 (de) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Neue therapeutische konzepte zur behandlung von gefässerkrankungen
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
NZ723459A (en) 2013-03-14 2017-12-22 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various diseases
US10369133B2 (en) 2013-07-23 2019-08-06 The University Of Tennessee Research Foundation Immunosuppressive compounds and therapeutics
RU2672872C2 (ru) * 2014-01-10 2018-11-20 Фуджифилм Корпорэйшн Способ и устройство для прогнозирования эффективной дозы или восприимчивости к 5-гидрокси-1н-имидазол-4-карбоксамиду, способ определения количества ксантозинмонофосфата, а также средство и способ для лечения миелодиспластического синдрома
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US10603299B2 (en) 2016-06-02 2020-03-31 Steven Baranowitz Prevention and treatment of viral infections
WO2017210262A1 (en) 2016-06-02 2017-12-07 Steven Baranowitz Prevention and treatment of viral infections
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
US10835489B2 (en) * 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
CN110526885A (zh) * 2019-08-20 2019-12-03 上海英诺富成生物科技有限公司 麦考酚酸的前体药物及其制备方法
CN112121173B (zh) * 2020-08-22 2022-05-06 浙江大学 脂肪酸修饰的免疫抑制剂mmf及fk506纳米制剂及其制备方法和应用
JP2024508327A (ja) 2021-03-03 2024-02-26 サナ バイオテクノロジー，インコーポレイテッド 心筋細胞療法と併用する免疫抑制療法、及び関連する方法ならびに組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1173942A (en) * 1967-06-06 1969-12-10 Bellon Labor Sa Roger New 2,3-Dihydro-1,4-Benzoxazines
GB1261060A (en) * 1969-09-09 1972-01-19 Ici Ltd Phthalen-1-one derivatives
JPS5542995B2 (ko) * 1972-02-24 1980-11-04
US3825571A (en) * 1971-07-31 1974-07-23 Chugai Pharmaceutical Co Ltd Mycophenolic acid derivatives
JPS563353B2 (ko) * 1972-03-02 1981-01-24
JPS5529994B2 (ko) * 1972-03-02 1980-08-07
US3777020A (en) * 1972-08-14 1973-12-04 Lilly Co Eli Psoriasis treatment with mycophenolic acid
US3868454A (en) * 1972-08-14 1975-02-25 Lilly Co Eli Psoriasis treatment with mycophenolic acid derivatives
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
US3905894A (en) * 1973-10-02 1975-09-16 Murskauskone Oy Apparatus for wet fine screening
JPS5724380A (en) * 1980-07-22 1982-02-08 Chugai Pharmaceut Co Ltd Preparation of mycophenolic acid derivative
JPS57183777A (en) * 1981-05-01 1982-11-12 Ajinomoto Co Inc Preparation of mycophenolic acid derivative
JPS57183776A (en) * 1981-05-01 1982-11-12 Ajinomoto Co Inc Preparation of mycophenolic acid derivative
IT1150194B (it) * 1982-02-23 1986-12-10 Chiesi Farma Spa Formulazioni farmaceutiche ad attivita'antiinfiammatoria, analgesica,antipiretica e gastroprotettiva

Also Published As

Publication number Publication date
MX9203163A (es) 1992-07-31
HU201927B (en) 1991-01-28
DK658787D0 (da) 1987-12-15
GR3002866T3 (en) 1993-01-25
LV5748B4 (lv) 1997-02-20
AU8254087A (en) 1988-08-04
US4786637A (en) 1988-11-22
ATE68180T1 (de) 1991-10-15
CA1333285C (en) 1994-11-29
HU210350A9 (en) 1995-03-28
PH23819A (en) 1989-11-23
NO1997007I1 (no) 1997-07-01
NO875240L (no) 1988-08-01
DE3773660D1 (de) 1991-11-14
GEP20094816B (en) 2009-11-10
PT86343B (pt) 1991-02-08
JPH0571591B2 (ko) 1993-10-07
FI875502A0 (fi) 1987-12-15
AU599728B2 (en) 1990-07-26
DK166675B1 (da) 1993-06-28
ZA879414B (en) 1989-08-30
IL84833A (en) 1992-03-29
US4952579A (en) 1990-08-28
NZ222922A (en) 1990-09-26
IE60750B1 (en) 1994-08-10
EP0281713B1 (en) 1991-10-09
LU88795I2 (fr) 1996-11-05
HUT47567A (en) 1989-03-28
FI85141B (fi) 1991-11-29
DE19675020I2 (de) 2002-11-07
JPS63188672A (ja) 1988-08-04
US4753935A (en) 1988-06-28
NO171680B (no) 1993-01-11
IE873397L (en) 1988-07-30
US4992467A (en) 1991-02-12
EP0281713A1 (en) 1988-09-14
FI875502A (fi) 1988-07-31
DK658787A (da) 1988-07-31
NL960019I2 (nl) 1997-06-02
US4868153A (en) 1989-09-19
NO875240D0 (no) 1987-12-15
LV5748A4 (lv) 1996-10-20
HK125893A (en) 1993-11-19
FI85141C (fi) 1992-03-10
US4948793A (en) 1990-08-14
IL84833A0 (en) 1988-06-30
KR940003758B1 (ko) 1994-04-30
NO171680C (no) 1993-04-21
ES2038190T3 (es) 1993-07-16
US4808592A (en) 1989-02-28
NL960019I1 (nl) 1996-10-01
PT86343A (en) 1988-01-01

Similar Documents

Publication Publication Date Title
KR880009016A (ko) 마이코페놀산의 모르폴리노에틸에스테르 및 이의 유도체
KR930000486A (ko) 광학활성 퀴놀린메발론산의 디아스테레오머염
KR910006272A (ko) 아미노 알콜의 티에닐카복실레이트, 이의 4급 생성물, 및 이들 화합물의 제조방법 및 용도
ATE37186T1 (de) Steroid carbonsaeureester.
SE8604950L (sv) Demensforbettrande och terapeutiska medel
KR930016402A (ko) 항-hiv 활성을 갖는 이미다졸 유도체
FI881816A0 (fi) Nya bicykliska foereningar, foerfarane foer deras framstaellning och dessa innehaollande farmaceutiska blandningar.
NO891286L (no) Fremgangsmaate for fremstilling av nye alkanfenoner.
SE7608203L (sv) Forfarande for framstellning av substituerade difenylsulfider
FI833647A (fi) Fenyl-indenderivat, deras syraadditionssalt och foerfarande foer deras framstaellning
DK479688A (da) Substituerede 3-aminosydnoniminer og farmakologisk acceptable syreadditionssalte deraf, deres fremstilling og anvendelse
FI810255L (fi) Nya 17-amino-16-hydroxisteroider ur androstan- och estranserier och deras derivat foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska kompositioner
ES416311A1 (es) Un procedimiento de preparacion de esteres dialquilaminoal-quilicos del acido 2-(6-metoxi-2-naftil) propionico.
PT92175A (pt) Processo para a preparacao de 3-amino-sidnoniminas substituidas e de produtos intermediarios farmacologicamente activos
SE8204791D0 (sv) Process for preparing alkoxy-vincaminic acid esters and alkoxy-apovincaminic acid esters
DE3882956D1 (de) Gegen die zerebrale insuffizienz wirksame verbindungen.
SE8405332D0 (sv) 2h-azeto(2,1-a)-isoquinoline derivatives, process for their preparation and pharmaceutical compositions containing them
KR880000449A (ko) 세펨 유도체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080331

Year of fee payment: 15

EXPY Expiration of term